Nat Commun 2022; 13:4785.○ This reference is of outstanding importance because it describes the binding properties and inhibitor activity of IDH1 inhibitors such as olutasidenib and ivosidenib against single mutant and double mutant IDH1 acute myeloid leukemia cells. This evidence concerns the gene IDH1 and acute myeloid leukemia.